Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca agrees to acquire rights to Actavis' lung drugs for $600m AstraZeneca has entered into a definitive agreement to acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of $600m. Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Columbia to begin Phase II trial of lidocaine bioadhesive 10% gel
By PBR Staff Writer
US-based Columbia Laboratories (CBRX) is planning to start a Phase II clinical trial for COL-1077, a lidocaine bioadhesive 10% gel, in women undergoing transvaginal pipelle-directed endometrial biopsy.
News
ObsEva releases positive results from Phase I trial of OBE001 to treat preterm labour
By PBR Staff Writer
Swiss biopharmaceutical firm ObsEva has reported positive results from a Phase I drug interaction trial of its new orally active oxytocin receptor antagonist, OBE001, designed to treat preterm labour.
News

Contract Research

Teva's Phase IIb chronic migraine trial of TEV-48125 meets primary and secondary endpoints
By PBR Staff Writer
Israel-based Teva Pharmaceutical Industries has reported positive results from a Phase IIb trial of two doses of subcutaneous TEV-48125, an investigational anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of chronic migraine.
News
NGM, Merck collaborate to develop biologic therapies for various diseases
By PBR Staff Writer
NGM Biopharmaceuticals and Merck have collaborated to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas.
News

Contract Services

Ipsen secures option to buy Canbex Therapeutics
By PBR Staff Writer
French pharmaceutical firm Ipsen has entered into option agreement to acquire 100% shares of UK's Canbex Therapeutics following completion of the Phase IIa trial of its orally active small molecule compound VSN16R, which is designed to treat spasticity in people with multiple sclerosis (MS).
News
Merck, MPP to expand access to pediatric formulations of HIV drug raltegravir
By PBR Staff Writer
Merck has signed an agreement with the Medicines Patent Pool (MPP) to allow the use of its HIV drug, Isentress (raltegravir), to treat children aged four weeks to 12 years in developing countries.
News